Truist lowered the firm’s price target on Beyond Air to $10 from $14 and keeps a Buy rating on the shares. Beyond Air introduced revenue guidance, targeting $12M-$16M for FY25, and Truist thinks several catalysts ahead should make the guidance achievable, the analyst tells investors in a research note. The expected cash burn of $10M per quarter against a cash balance of $43M and financing availability of $22M should support operations through FY25, but does raise solvency concern before profitability, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on XAIR:
- Beyond Air reports Q2 EPS (51c), consensus (47c)
- Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024
- XAIR Upcoming Earnings Report: What to Expect?
- Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
- Beyond Cancer presents first-in-human clinical data for UNO therapy